Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy
1997

Topotecan for Advanced Breast and Lung Cancer

Sample size: 25 publication Evidence: low

Author Information

Author(s): PN Mainwaring, MC Nicolson, T Hickish, R Penson, S Joel, M Slevin, IE Smith

Primary Institution: Royal Marsden NHS Trust; St Bartholomew's Hospital

Hypothesis

Infusional topotecan might have superior activity to conventional schedules.

Conclusion

Infusional topotecan does not appear to offer a clinical advantage over conventional 5-day schedules against advanced NSCLC and advanced breast cancer.

Supporting Evidence

  • Three patients achieved a partial response: one with NSCLC and two with advanced breast cancer.
  • The major toxicities were neutropenia and thrombocytopenia.
  • Median duration of survival was 41 weeks for NSCLC patients and 52 weeks for breast cancer patients.

Takeaway

Doctors tested a new way to give a cancer medicine called topotecan, but it didn't work better than the old way.

Methodology

Two open, phase II studies evaluated the activity and toxicity of infusional topotecan in patients with advanced NSCLC and advanced breast cancer.

Limitations

The study was terminated early due to lack of evidence supporting the hypothesis of increased activity for infusional topotecan.

Participant Demographics

{"total":25,"NSCLC":{"male":10,"female":2,"age_range":"39-65 years","median_age":46},"breast_cancer":{"male":0,"female":13,"age_range":"40-73 years","median_age":50}}

Statistical Information

Confidence Interval

{"NSCLC":"95% CI 0-39%","breast_cancer":"95% CI 2-45%"}

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication